LetterThe Real Value of Stereotactic Ablative Radiotherapy (SABR) in Oligometastases: A Journey Into the Literature Evidence
Section snippets
Funding
Not available.
Conflict of interest
The authors declare no conflict of interest.
References (14)
- et al.
Stereotactic ablative radiotherapy for oligometastatic disease: great enthusiasm but scant evidence
Clin Oncol
(2022) - et al.
A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study
Radiother Oncol
(2022) - et al.
Evaluation of Italian radiotherapy research from 1985 to 2005: preliminary analysis
Radiol Med
(2019) - et al.
Efficacy of stereotactic body radiotherapy in oligorecurrent and in oligoprogressive prostate cancer: new evidence from a multicentric study
Br J Cancer
(2017) - et al.
Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial
JAMA Oncol
(2018) - et al.
Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study
J Clin Oncol
(2019) - et al.
First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332)
J Clin Oncol
(2020)
There are more references available in the full text version of this article.
Cited by (0)
© 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.